Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs ProShares Ultra Gold ETF (UGL) Price & Performance

Amylx Pharmaceuticals IncTrade
ProShares Ultra Gold ETFTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs ProShares Ultra Gold ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while ProShares Ultra Gold ETF trades at $52.3. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals.

AMLXUGL
Market Cap
$2.53B
Sector
HealthLeveraged / Inverse
52-Week High
$24.19$85.62
52-Week Low
$7.82$34.37
Enterprise Value
$2.28B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

ProShares Ultra Gold ETF

UGL trades at $50.69, up 4.45% in 24 hours, with a bullish technical signal driven by moving averages. The stock shows strong momentum but faces overbought conditions with a 6-day RSI at 85.76. Recent news highlights gold's rebound potential, with analysts projecting prices toward $4,500–$5,000 per ounce, benefiting gold-related equities.

The outlook for UGL is positive amid supportive gold market dynamics, though high RSI levels suggest near-term consolidation risks. Investment appeal hinges on sustained gold strength, while exposure to commodity volatility and Fed policy shifts remain key watchpoints for shareholders.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About ProShares Ultra Gold ETF

UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.

Read more on UGL